Early stage American biopharmaceutical company which develops treatments based on blocking Pannexin 1 channels, membrane channels involved in cell signalling, inflammation and tumour growth. Came out of academic research on those channels and has been supported by biotechnology accelerators, and works on preclinical candidates aimed at cancer and related conditions.
No comments available.
Leave your rating & comment